Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$27.98 USD
-0.07 (-0.25%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $27.99 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.98 USD
-0.07 (-0.25%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $27.99 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Royalty Pharma (RPRX) Surges 5.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Royalty Pharma (RPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Royalty Pharma (RPRX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 5.80% and 3.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Aug 12, 2021
by Zacks Equity Research
Companies In The News Are: WEN, HAE, RPRX, BLI
Royalty Pharma (RPRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.43% and 0.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Royalty Pharma (RPRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Constellation (CNST) Surges on Takeover Deal With MorphoSys
by Zacks Equity Research
Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.
Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SYF or RPRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYF vs. RPRX: Which Stock Is the Better Value Option?
SYF vs. RPRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SYF vs. RPRX: Which Stock Is the Better Value Option?
CIXX or RPRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CIXX vs. RPRX: Which Stock Is the Better Value Option?
Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?
by Zacks Equity Research
Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.
Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Allergan Inks Deal to Buy Texas-Based Repros Therapeutics
by Zacks Equity Research
Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.
What's in the Cards for Repros (RPRX) This Earnings Season?
by Zacks Equity Research
Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
Repros' Proellex Stays on Partial Clinical Hold, Shares Fall
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.
What's in the Cards for Repros (RPRX) this Earnings Season?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.
Repros' Proellex Continues to be Under Partial Clinical Hold
by Zacks Equity Research
Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.
Repros to Meet with the FDA for Phase III Proellex Program
by Zacks Equity Research
Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.